CD8A and cancer: Remarkably, high tumor infiltration by CD8+ T cells and CD8+CD103+ resident memory T cells correlated with better survival for treatment-naive cancer patients and, to some extent, improved response to immune checkpoint blockade (ICB) [12–14].